The IMMUFELLOW postdoctoral programme has opened its first Call for Applications. The programme will recruit a total of 22 international postdoctoral researchers working with immunology-related projects to the University of Turku and Åbo Akademi University in two Calls during 2025–2030.
Professor Shimon Sakaguchi, winner of the 2025 Nobel Prize in Medicine, is a visiting professor at the IMMUNOCAPs project that profiles research at the University of Turku. The news of Sakaguchi's award was celebrated at Turku.
Vaccines trigger a notably rapid response in the stromal cells of draining lymph nodes within the first hours after administration. Researchers at the University of Turku and the InFLAMES Flagship in Finland also discovered that the stromal alterations prime the lymph node landscape for the subsequent steps of vaccine-induced immune responses.
MediCity Research Laboratory opens a call for grant applications. The purpose of the grant is scientific research related to a collaborative project on the causal role, mechanistic impact, and therapeutic targeting of Human Cytomegalovirus (HCMV) in brain cancer lead by Professor Cecilia Söderberg-Nauclér, InFLAMES group leader.
MediCity Research Laboratory opens a call for grant applications. The purpose of the grant is scientific research related to a collaborative project on the causal role, mechanistic impact, and therapeutic targeting of Human Cytomegalovirus (HCMV) in brain cancer lead by Professor Cecilia Söderberg-Nauclér, InFLAMES group leader.
MediCity Research Laboratory opens a call for grant applications. The purpose of the grant is scientific research related to a collaborative project on the causal role, mechanistic impact, and therapeutic targeting of Human Cytomegalovirus (HCMV) in brain cancer lead by Professor Cecilia Söderberg-Nauclér, InFLAMES group leader.
MediCity Research Laboratory opens a call for grant applications. The purpose of the grant is scientific research related to a collaborative project on the causal role, mechanistic impact, and therapeutic targeting of Human Cytomegalovirus (HCMV) in brain cancer lead by Professor Cecilia Söderberg-Nauclér, InFLAMES group leader.
Researchers at the University of Turku, Finland, have taken a step towards more personalised and effective cancer treatments. A new study has identified the conditions under which the antibody drug bexmarilimab can activate the body's own defence system against cancer, and how to identify patients who will benefit from the drug. The study was published in the Journal for ImmunoTherapy of Cancer.
Professor Cecilia Söderberg-Nauclér, InFLAMES group leader from the University of Turku, is investigating the links between human cytomegalovirus and brain tumours in a multi-million euro research project conducted in collaboration between researchers in Finland, Denmark, and Sweden. The Lundbeck Foundation has awarded a grant of approximately €4 million for the project.